Hemostemix Inc. Share Price

HEM

CA4236943060

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 20:20:17 20/07/2026 BST			5-day change	1st Jan Change
0.0650 ^CAD	0.00%		+8.33%	-27.78%

07-08	Hemostemix Files Commercialization Application for Treatment of Vascular Dementia, Refractory Angina and Pain	MT
06-26	Hemostemix Raises C$360,000 in the First Tranche of Private Placement of Share Units	MT

News in other languages: Hemostemix Inc.

10/02/25	Hemostemix : Casino auf gold
15/01/25	Hemostemix: Klininsche Studien bescheinigen bahnbrechende Stammzelltherapie
22/04/21	Hemostemix : (German Translation) Hemostemix gibt den Abschluss der Nachbeobachtung von Studienteilnehmern der klinischen Phase-II-Studie bekannt und Uplisting von HMTXF
09/04/21	Hemostemix : (German Translation – April 8, 2021)

More news

Managers and Directors: Hemostemix Inc.

Manager	Title	Age	Since
Thomas Smeenk CEO	Chief Executive Officer	-	09/02/2020
Christina Wu DFI	Director of Finance/CFO	-	04/03/2020
Fraser Henderson CTO	Chief Tech/Sci/R&D Officer	-	13/10/2021

Director	Title	Age	Since
Thomas Smeenk BRD	Director/Board Member	-	25/11/2019
Ronnie Hershmann BRD	Director/Board Member	67	08/02/2020
Loran Swanberg BRD	Director/Board Member	-	07/04/2020

More insiders

Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patientâ€™s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patientâ€™s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
20/07/26	CA$0.0650	0.00%	31,911
17/07/26	CA$0.0650	0.00%	33,911
16/07/26	CA$0.0650	0.00%	34,029
15/07/26	CA$0.0650	+8.33%	131,911

Delayed Quote Toronto S.E.

More quotes

Income Statement and Estimates

More financial data

Market Cap	12.86M 9.15M 8.02M 7.41M 6.81M 882M 13.06M 88.6M 34.73M 432M 34.34M 33.59M 1.49B	P/E 2024	-4.36x	P/E 2025	-3.12x
Enterprise Value	15.72M 11.18M 9.8M 9.06M 8.33M 1.08B 15.97M 108M 42.46M 528M 41.98M 41.07M 1.82B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	82.86%	Yield 2024 *	-	Yield 2025	-

07-08	Hemostemix Files Commercialization Application for Treatment of Vascular Dementia, Refractory Angina and Pain	MT
06-26	Hemostemix Raises C$360,000 in the First Tranche of Private Placement of Share Units	MT
06-16	Hemostemix Inc. amended terms of the transaction	CI
05-29	Hemostemix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-25	Hemostemix Inc. Announces the Appointment of Desire´e Cox to Board of Directors	CI
05-20	Hemostemix Inc. announced that it expects to receive CAD 1 million in funding	CI
05-01	Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-30	Hemostemix Inc. Auditor Raises 'Going Concern' Doubt	CI
03-18	Hemostemix Inc. announced that it has received CAD 0.783968 million in funding	CI
01-16	Hemostemix Receives FDA Support for Its Basket Protocol Approach	MT
12-30	Hemostemix Inc. announced that it has received CAD 0.48 million in funding	CI
12-23	Hemostemix Inc Appoints David B. Alper as Member of Scientific Advisory Board, Effective January 2026	CI
12-09	Hemostemix Inc. announced that it expects to receive CAD 0.96 million in funding	CI

07-08	Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain	NE
06-26	Hemostemix Closes $360,000 First Tranche of Private Placement	NE
06-17	Hemostemix : rsquo; $1,000,000 Private Placement and Update	PU
06-17	Hemostemix' $1,000,000 Private Placement and Update	NE
05-26	Dr. Desiree Cox Appointed to Hemostemix Board of Directors	AQ

1 week	+8.33%
Current month	+18.18%
1 month	+30.00%
3 months	+8.33%
6 months	-27.78%
Current year	-27.78%

1 week	0.06	0.07
1 month	0.04	0.07
Current year	0.04	0.11
1 year	0.04	0.14
3 years	0.04	0.42
5 years	0.04	0.42
10 years	0	5.9

Hemostemix Inc. Share Price

Stocks

HEM

CA4236943060

Biotechnology & Medical Research

Valuation: Hemostemix Inc.

Chart: Hemostemix Inc.

Latest news : Hemostemix Inc.

Press Releases: Hemostemix Inc.

News in other languages: Hemostemix Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Hemostemix Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Date	Insider	Type	Main position	Quantity	% Market Cap.
25/06/26	Peter Lacey	Sell	Chairman	1,000,000	0.5056%
25/06/26	Peter Lacey	Sell	Chairman	2,000,000	1.0111%
18/12/25	Loran Swanberg	Option	Director	65,000	0.0345%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HEMOSTEMIX INC.	0.00%	+8.33%	-51.85%	-43.48%	9.18M
ARGENX SE	+0.21%	-0.79%	+53.17%	+57.39%	53.83B
WUXI APPTEC CO., LTD.	+5.37%	+3.31%	+50.39%	+83.65%	52.1B
INSMED INCORPORATED	-1.20%	-1.94%	+4.35%	+402.68%	23.48B
BIONTECH SE	+0.74%	+2.32%	-16.23%	-14.44%	23.13B
WUXI BIOLOGICS (CAYMAN) INC.	+3.46%	+2.52%	+34.01%	-5.41%	19.36B
GENMAB A/S	-1.18%	-2.97%	+30.12%	-33.30%	17.56B
PHARMAESSENTIA CORPORATION	-1.67%	-6.00%	+163.95%	+284.69%	15.2B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.62%	0.00%	+29.70%	+643.91%	14.83B
EXELIXIS, INC.	-0.70%	-0.91%	+24.87%	+179.47%	14.06B
Average	+0.87%	-0.60%	+32.25%	+155.52%	23.36B
Weighted average by Cap.	+1.48%	-1.49%	+41.46%	+138.19%

	2024	2025
Net sales	-	-
Net income	-2.62M -1.86M -1.63M -1.51M -1.39M -179M -2.66M -18.03M -7.07M -87.8M -6.99M -6.84M -303M	-4.71M -3.35M -2.94M -2.72M -2.5M -323M -4.79M -32.48M -12.73M -158M -12.59M -12.32M -545M
Net Debt	4.23M 3.01M 2.64M 2.44M 2.24M 290M 4.3M 29.15M 11.43M 142M 11.3M 11.05M 489M	2.86M 2.03M 1.78M 1.65M 1.52M 196M 2.91M 19.71M 7.73M 96.01M 7.64M 7.47M 331M